Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

被引：7

作者：

Wang, Yaning ^{[1
]}

Chen, Wanqi ^{[1
]}

Shi, Yixin ^{[1
]}

Yan, Chengrui ^{[2
]}

Kong, Ziren ^{[3
]}

Wang, Yuekun ^{[1
]}

Wang, Yu ^{[1
]}

Ma, Wenbin ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China

[2] Peking Univ Int Hosp, Dept Neurosurg, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Head & Neck Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

glioblastoma; targeted therapy; phase III trial; phase II trial; overall survival; NEWLY-DIAGNOSED GLIOBLASTOMA; CEREBRAL BLOOD-VOLUME; HEPATOCYTE GROWTH-FACTOR; OPEN-LABEL; RANDOMIZED-TRIAL; DOUBLE-BLIND; PROTEASOME INHIBITORS; MONOCLONAL-ANTIBODY; STANDARD TREATMENT; RADIATION-THERAPY;

D O I：

10.3389/fonc.2021.719623

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The most common primary intracranial tumor is glioma, among which glioblastoma (GBM) has the worst prognosis. Because of the high degree of malignancy of GBM and frequent recurrence after surgery, postoperative therapy, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, is particularly important. A wide variety of targeted drugs have undergone phase III clinical trials for patients with GBM, but these drugs do not work for all patients, and few patients in these trials have prolonged overall survival. In this review, some imposing phase III clinical trials of targeted drugs for glioma are introduced, and some prospective phase II clinical trials that have been completed or are in progress are summarized. In addition, the mechanisms of these drugs are briefly introduced, and deficiencies of these clinical trials are analyzed. This review aims to provide a comprehensive overview of current research on targeted drugs for glioma to clarify future research directions.

引用

页数：13

共 50 条

[1] Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma
Wang, Yuekun
Li, Shenglan
Peng, Yichen
Ma, Wenbin
Wang, Yu
Li, Wenbin
[J]. CANCER INNOVATION, 2023, 2 (02): : 114 - 130
[2] Current phase II and phase III clinical trials in the treatment of colorectal cancer
Mooney, MM
Schoenfeldt, M
[J]. ONCOLOGY-NEW YORK, 2004, 18 (11): : 1396 - +
[3] Emerging drugs for hemophilia A: insights into phase II and III clinical trials
Kizilocak, Hande
Young, Guy
[J]. EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (04) : 337 - 350
[4] Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
Tremblay, Douglas
Hoffman, Ronald
[J]. EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (04) : 351 - 362
[5] Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
Mandel, Jacob J.
Yust-Katz, Shlomit
Patel, Akash J.
Cachia, David
Liu, Diane
Park, Minjeong
Yuan, Ying
Kent, Thomas A.
de Groot, John F.
[J]. NEURO-ONCOLOGY, 2018, 20 (01) : 113 - 122
[6] Current phase II and phase III clinical trials for pancreatic cancer - Referral resource
Mooney, MM
Schoenfeldt, M
[J]. ONCOLOGY-NEW YORK, 2004, 18 (08): : 1008 - +
[7] Trends and progress in phase III clinical trials on targeted agents in advanced cancers.
Nguyen, T.
Ueda, S. M.
Shin, J.
Tan, J.
Hoff, J.
Monk, B. J.
Osann, K.
Kapp, D. S.
Chan, J. K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials
Lockwood, Jonathan Tomas
Remington, Gary
[J]. EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (03) : 407 - 421
[9] Current Status of Clinical Trials for Glioblastoma
Salgaller, Michael L.
Liau, Linda M.
[J]. REVIEWS ON RECENT CLINICAL TRIALS, 2006, 1 (03) : 265 - 281
[10] The disconnect between phase II and phase III trials of drugs for heart failure
Muthiah Vaduganathan
Stephen J. Greene
Andrew P. Ambrosy
Mihai Gheorghiade
Javed Butler
[J]. Nature Reviews Cardiology, 2013, 10 : 85 - 97

← 1 2 3 4 5 →